imdusiran (AB-729) / Arbutus  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
imdusiran (AB-729) / Arbutus
NCT04847440: A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

Terminated
2a
40
RoW
ATI-2173, Viread, tenofovir disoproxil fumarate, AB-729
Antios Therapeutics, Inc
Hepatitis B, Chronic, Hepatitis D
09/22
09/22
ACTRN12622000317796: Study Investigating the Safety and Immunogenicity of AB-729 and VTP 300 in Virologically Suppressed CHB Participants

Recruiting
2
40
 
Arbutus Biopharma, Arbutus Biopharma
Virologically-Suppressed Chronic Hepatitis B
 
 
NCT04820686: A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Terminated
2
65
Europe, Canada, RoW
VBR, Vebicorvir, ABI-H0731, AB-729, SOC NrtI, Entecavir (ETV), Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF)
Assembly Biosciences, Arbutus Biopharma Corporation
Chronic Hepatitis B
03/23
03/23
NCT04980482: Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Active, not recruiting
2
43
US, RoW
AB-729, Peg-IFNα-2a, pegylated interferon alpha 2a
Arbutus Biopharma Corporation
Chronic Hepatitis b
05/24
04/25
NCT06245291: Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Recruiting
2
30
Europe, RoW
Imdusiran, Durvalumab
Arbutus Biopharma Corporation
Hepatitis B, Chronic
02/27
07/27
i-LIVER, NCT06154278: Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Not yet recruiting
2
10
NA
Imdusiran (AB-729)
University of Maryland, Baltimore, Arbutus Biopharma Corporation
Chronic Hepatitis B
12/26
07/27

Download Options